3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Neoplasm Metastasis
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Stomach Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
7
Fluorouracil
5
Cisplatin
5
Leucovorin
3
becatecarin
2
Oxaliplatin
2
Capecitabine
2
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
spartalizumab
1
seribantumab
1
sargramostim
1
pembrolizumab
1
motexafin lutetium
1
ixabepilone
1
incomplete Freund's adjuvant
1
durvalumab
1
cediranib
1
Trastuzumab
1
Sutures
1
Surgical Instruments
1
Standard of Care
1
S 1 (combination)
1
Radiotherapy
1
Radiosurgery
1
Palonosetron
1
Observation
1
Liver Transplantation
1
Ligation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Bile Duct Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts